EXTENSIVE EVIDENCE REDEFINES RISK REDUCTION FOR PATIENTS WITH PAD1,2

EXPLORE THE EVIDENCE

The XARELTO® vascular dose* is the FIRST and ONLY treatment approach indicated to help reduce the risk of major thrombotic vascular events† in patients with PAD, including patients after recent LER due to symptomatic PAD.1,2

Learn more about the clinical profiles of the 2 landmark studies that support the XARELTO® vascular dose.*2,3

CAD = coronary artery disease; CV = cardiovascular; LER = lower extremity revascularization; PAD = peripheral artery disease.

*XARELTO® 2.5 mg twice daily plus aspirin (100 mg in clinical trial; 75 mg to 100 mg in practice) once daily.
†Reduction of a composite of myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology.

Next: PAD Efficacy Profile

References: 1. XARELTO® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994-2004. 3. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: Net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020;142(1):40-48.